Self-Sampling Using Colli-Pee® Device for HPV Screening Is Both Cost Effective and Could Improve Patient Access, Study Concludes

OraSure Technologies has conducted a study that suggests self-sampling with its Colli-Pee® device is a cost-effective alternative to clinician-collected sampling and other self-sampling methods for routine human papillomavirus (HPV) primary cervical cancer screening. The study, published in the biomedical journal “BMJ Open,” indicates that if self-screening led to a 15% increase in women accessi..